BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price rose 9.4% during trading on Friday . The company traded as high as $2.60 and last traded at $2.57, with a volume of 1,269,093 shares traded. The stock had previously closed at $2.35.

BDSI has been the topic of a number of analyst reports. FBR & Co reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $4.00 target price (down previously from $6.00) on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Cantor Fitzgerald cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their target price for the stock from $9.00 to $5.00 in a research report on Wednesday, May 11th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Janney Montgomery Scott reiterated a “hold” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $8.25.

The stock’s 50-day moving average price is $2.44 and its 200-day moving average price is $3.06. The stock’s market cap is $136.66 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The firm had revenue of $3 million for the quarter, compared to analysts’ expectations of $2.96 million. During the same period in the previous year, the business posted ($0.16) earnings per share. BioDelivery Sciences International’s quarterly revenue was down 77.1% on a year-over-year basis. On average, equities analysts expect that BioDelivery Sciences International Inc. will post ($1.17) EPS for the current fiscal year.

Several institutional investors recently modified their holdings of the company. Russell Frank Co raised its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares in the last quarter. Sei Investments Co. raised its position in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares in the last quarter. Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares in the last quarter. Royce & Associates LLC raised its position in shares of BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock worth $7,127,000 after buying an additional 87,200 shares in the last quarter. Finally, 1492 Capital Management LLC raised its position in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares in the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.